Rezpegaldesleukin (REZPEG/NKTR-358)
Rezpegaldesleukin (REZPEG/NKTR-358)
REZPEG (NKTR-358) is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions.
Research suggests that suboptimal levels of Treg cells, powerful inhibitory immune cells, and lack of Treg cell activity may underlie the development of autoimmune and inflammatory diseases, including lupus and psoriasis.
REZPEG(NKTR-358) works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease. Activation of Tregs suppresses disease-causing T cells and restores the body’s self-tolerance mechanisms.
2025 American Academy of Dermatology (AAD) Annual Meeting
2024 Nature Publication
- Article: “The regulatory T cell-selective interleukin-2 receptor against rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials“, Silverberg, et al.
2024 European Academy of Dermatology and Venereology (EADV) Congress
- ePoster P0662: “Serum proteomic biomarker analysis of the interleukin-2 receptor pathway agonist rezpegaldesleukin in patients with atopic dermatitis“, Yu, D.
- ePoster P0600 (Trial in Progress): “A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, International, Multicenter, Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis“, Gkalpakiotis, S.
- ePoster P2080 (Trial in Progress): “A Phase 2b Study Evaluating the Efficacy and Safety of Single Agent Rezpegaldesleukin, an Interleukin-2 Receptor (IL-2R) Pathway Agonist, in the Treatment of Severe to Very Severe Alopecia Areata“, Reich, A.
Revolutionizing Atopic Dermatitis (RAD) Conference 2024
- TiP Abstract 117-1000729: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, International, Multicenter, Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis
Revolutionizing Alopecia Areata (RAA) Conference 2024
- TiP Abstract 116-1000724: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Severe to Very-Severe Alopecia Areata
13th World Congress for Hair Research
2023 EADV Congress
- Abstract 6685: Efficacy and Safety of Single Agent Rezpegaldesleukin, a Selective Regulatory T-Cell-Inducing Interleukin-2 Conjugate, in the Treatment of Atopic Dermatitis: Final Results from a Randomized Phase 1b Study
- Abstract P0559: A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis
2021 Journal of Translational Autoimmunity
2020 ACR Convergence 2020 Meeting
- Presentation: NKTR-358: Selective Expansion of Regulatory T Cells in Patients with Systemic Lupus Erythematosus by a Novel IL-2 Conjugate
2020 European E-Congress of Rheumatology (EULAR)
- Presentation: NKTR-358: A PEG-conjugated rhIL-2 that selectively induces Tregs and their suppressive activity
The Promise of Interleukin-2 Therapy Meeting, Paris, France
2019 EULAR European Congress of Rheumatology
2019 American College of Rheumatology Annual Meeting
2019 EULAR European Congress of Rheumatology
Treg Directed Therapy for Autoimmune Disorders Meeting – May 2018
Antigen-Specific Immune Tolerance Drug Development Summit – April 2018
- Presentation: NKTR-358: A Selective Regulatory T Cell Inducing Agent for the Treatment of Autoimmune and Inflammatory Diseases
American College of Rheumatology Annual Meeting, San Diego, CA
- Poster Abstract 2715: NKTR-358: A Selective, First-in-Class IL-2 Pathway Agonist Which Increases Number and Suppressive Function of Regulatory T Cells for the Treatment of Immune Inflammatory Disorders, Langowski, J., et al.
13th Annual World Congress on Inflammation
- Oct 7, 2019: Nektar Therapeutics Announces Initiation of Two Clinical Studies of Novel T Regulatory Cell Stimulator REZPEG (NKTR-358) (LY3471851) in Patients with Psoriasis and Atopic Dermatitis
- Jun 13, 2019: First-in-Human Data Presented from Phase 1a Study of REZPEG (NKTR-358), a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology
- May 8, 2018: Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of REZPEG (NKTR-358), a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
- July 24, 2017: Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize REZPEG (NKTR-358), A Novel Autoimmune Therapy
- July 10, 2017: Nektar Presents New Preclinical Data for REZPEG (NKTR-358), a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London
- March 27, 2017: Nektar Therapeutics Initiates Clinical Study of REZPEG (NKTR-358), a First-in-Class Regulatory T Cell Stimulator, Being Developed for the Treatment of Immune and Inflammatory Disorders
